To compile the report, athenaResearch analyzed more than 60,000 prescriptions for epinephrine auto-injectors written for 50,000 patients across the country since the start of 2016.
In December 2016, 5.3 percent of prescriptions represented alternative epinephrine auto-injector devices. This February, that figure spiked to 28.9 percent of total prescriptions.
New generic EpiPen options entering the market, along with changes from insurers, may be responsible for the sudden jump, the report suggests.
More articles on supply chain:
10 drugmakers with highest direct-to-consumer ad spending in 2016
The ‘price hikes fuel innovation’ argument is invalid, researchers say
Trump’s Supreme Court nominee advocates legal protection for devicemakers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
